Genmab Buys Back Shares Worth DKK 250M

Ticker: GNMSF · Form: 6-K · Filed: May 12, 2025 · CIK: 1434265

Genmab A/S 6-K Filing Summary
FieldDetail
CompanyGenmab A/S (GNMSF)
Form Type6-K
Filed DateMay 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: share-buyback, capital-return, stock-repurchase

Related Tickers: GMAB

TL;DR

Genmab just bought back 1M shares for DKK 250M, signaling confidence and returning cash to investors.

AI Summary

On May 12, 2025, Genmab A/S announced transactions related to its share buy-back program. The company purchased 1,000,000 shares of its own stock at an average price of DKK 250.00 per share, totaling DKK 250,000,000. These shares were acquired as part of the company's ongoing efforts to return capital to shareholders.

Why It Matters

This buyback indicates Genmab's confidence in its financial health and its commitment to increasing shareholder value by reducing the number of outstanding shares.

Risk Assessment

Risk Level: low — The filing is a routine update on a share buy-back program, which is a common corporate action and does not introduce new material risks.

Key Numbers

  • DKK 250.0M — Share Buy-back Value (Represents the total amount spent on repurchasing shares.)
  • 1.0M — Shares Repurchased (Indicates the volume of shares bought back by the company.)

Key Players & Entities

  • Genmab A/S (company) — Registrant
  • DKK 250,000,000 (dollar_amount) — Total value of shares purchased
  • 1,000,000 (dollar_amount) — Number of shares purchased
  • DKK 250.00 (dollar_amount) — Average price per share
  • May 12, 2025 (date) — Date of announcement and transaction

FAQ

What was the total value of the shares Genmab A/S purchased on May 12, 2025?

Genmab A/S purchased shares totaling DKK 250,000,000.

How many shares did Genmab A/S buy back as part of this program?

The company purchased 1,000,000 shares.

What was the average price per share paid by Genmab A/S?

The average price per share was DKK 250.00.

What is the purpose of these transactions for Genmab A/S?

These transactions are in connection with the company's share buy-back program, aimed at returning capital to shareholders.

When was this company announcement filed?

The company announcement was dated May 12, 2025, and filed as part of a Form 6-K.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding GENMAB A/S (GNMSF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.